Business Context and Reporting Period
This Form 8-K Current Report was filed by Vanda Pharmaceuticals Inc. on July 1, 2010. The filing reports a corporate governance event: the election of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
The Board of Directors elected Steven K. Galson, M.D., as a director, effective July 1, 2010. His initial term expires at the 2012 annual meeting of stockholders. Consequently, the Board increased the total number of directors to seven. Dr. Galson is considered an independent director.
Compensation and Governance Details
- Initial Grant: Dr. Galson received an option to purchase 35,000 shares of common stock at the closing price on July 1, 2010. This option vests in equal monthly installments over four years, with acceleration upon a change of control.
- Annual Grant: He is eligible to receive an option to purchase 15,000 shares upon the conclusion of each annual meeting of stockholders. These options vest over one year.
- Cash Fees: Dr. Galson will receive an annual fee of $25,000, plus $2,500 for each in-person Board meeting and $1,250 for meetings attended by telephone.
- Indemnification: An indemnification agreement was entered into, protecting Dr. Galson to the fullest extent permitted under Delaware law.
Investor Verification Checklist
- Verify the closing stock price on July 1, 2010, to determine the exercise price of the initial 35,000 share option.
- Review the Company's Definitive Proxy Statement filed on April 28, 2010, for the full details of the outside director compensation program.
- Confirm Dr. Galson's independence status and potential conflicts of interest given his prior roles at the FDA and other government agencies.
- Check subsequent filings to confirm the vesting schedule and any changes to the Board composition.